Literature DB >> 7527017

Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains.

M D Scolnik1, C Servadio, A Abramovici.   

Abstract

The induction of prostatic lesions in the rat by hormonal manipulation and/or chemical carcinogens in different strains is well documented in literature. However, the selection of a strain for such studies was merely based on the laboratory husbandry facilities rather than on the animal genotype. It is well accepted that the morphology and function of the prostate exhibit a marked species-specific differences that makes extrapolation to other animals and man difficult. Our group has developed an experimental model for the study of rat prostatic hyperplasia and/or dysplasia induced by citral--a flavor constituent. Previous observations have revealed that the Wistar rat ventral prostate is reactive to citral, especially during its adolescent growth period as well as during the redifferentiation stage among postcastrated rats treated with exogenous testosterone. The present study presents data on the ventral prostate susceptibility of three additional strains selected by their interrelated endocrine morbidity. In order to facilitate an objective comparative analysis of the prostatic lesions a histopathological score chart was elaborated. The present findings showed that the Wistar and Sprague-Dawley strains were the most susceptible to developing benign and atypical prostatic hyperplasia both in intact and postcastrated rats. The F344 and ACl/Ztm rat strains remained refractory toward all of these treatments. Our data provide evidence that the strain genotype and, more precisely, their endocrine background, play a determinative role in the prostatic responsiveness towards citral. It is suggested that additional consideration be given to the selection of an adequate animal strain when studying experimental neoplastic transformation, especially when hormonal interactions might be involved.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527017

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  16 in total

1.  Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: an experimental study in a rat model of benign prostatic hyperplasia.

Authors:  Dong Yang; Teng Hou; Xiong Yang; Yan Ma; Longwang Wang; Bing Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-06-09

2.  Flaxseed reduces epithelial proliferation but does not affect basal cells in induced benign prostatic hyperplasia in rats.

Authors:  Ilma Cely de Amorim Ribeiro; Carlos Alberto Soares da Costa; Vivian Alves Pereira da Silva; Lanna Beatriz Neves Silva Côrrea; Gilson Teles Boaventura; Mauricio Alves Chagas
Journal:  Eur J Nutr       Date:  2016-02-08       Impact factor: 5.614

3.  Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.

Authors:  Ferenc G Rick; Andrew V Schally; Norman L Block; Mehrdad Nadji; Karoly Szepeshazi; Marta Zarandi; Irving Vidaurre; Roberto Perez; Gabor Halmos; Luca Szalontay
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

4.  Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia.

Authors:  Lingmin Song; Wenhao Shen; Heng Zhang; Qiwu Wang; Yongquan Wang; Zhansong Zhou
Journal:  Bosn J Basic Med Sci       Date:  2016-06-13       Impact factor: 3.363

5.  Effects of citral, a naturally occurring antiadipogenic molecule, on an energy-intense diet model of obesity.

Authors:  Tamonud Modak; Abhilash Mukhopadhaya
Journal:  Indian J Pharmacol       Date:  2011-05       Impact factor: 1.200

6.  Anti-inflammatory and antiproliferative activities of date palm pollen (Phoenix dactylifera) on experimentally-induced atypical prostatic hyperplasia in rats.

Authors:  Ahmed A Elberry; Shagufta T Mufti; Jaudah A Al-Maghrabi; Essam A Abdel-Sattar; Osama M Ashour; Salah A Ghareib; Hisham A Mosli
Journal:  J Inflamm (Lond)       Date:  2011-12-23       Impact factor: 4.981

7.  Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.

Authors:  Ekaterina A Lesovaya; Kirill I Kirsanov; Elena E Antoshina; Lubov S Trukhanova; Tatiana G Gorkova; Elena V Shipaeva; Ramiz M Salimov; Gennady A Belitsky; Mikhail V Blagosklonny; Marianna G Yakubovskaya; Olga B Chernova
Journal:  Oncotarget       Date:  2015

8.  Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate.

Authors:  Wenhao Zhang; Ning Zang; Yaoming Jiang; Ping Chen; Xinghuan Wang; Xinhua Zhang
Journal:  Sci Rep       Date:  2015-12-10       Impact factor: 4.379

9.  Immunomodulatory effect of red onion (Allium cepa Linn) scale extract on experimentally induced atypical prostatic hyperplasia in Wistar rats.

Authors:  Ahmed A Elberry; Shagufta Mufti; Jaudah Al-Maghrabi; Essam Abdel Sattar; Salah A Ghareib; Hisham A Mosli; Salah A Gabr
Journal:  Mediators Inflamm       Date:  2014-04-13       Impact factor: 4.711

10.  Lysozyme gene treatment in testosterone induced benign prostate hyperplasia rat model and comparasion of its' effectiveness with botulinum toxin injection.

Authors:  Osman Ergün; Pinar Aslan Koşar; İbrahim Onaran; Hakan Darici; Alim Koşar
Journal:  Int Braz J Urol       Date:  2017 Nov-Dec       Impact factor: 1.541

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.